Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record.

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Tse, Kam Fai, Jeffers, Michael, Pollack, Vincent A, McCabe, Denise A, Shadish, Melanie L, Khramtsov, Nikolai V, Hackett, Craig S, Shenoy, Suresh G, Kuang, Bing, Boldog, Ferenc L, MacDougall, John R, Rastelli, Luca, Herrmann, John, Gallo, Michael, Gazit-Bornstein, Gadi, Senter, Peter D, Meyer, Damon L, Lichenstein, Henri S, LaRochelle, William J · 2006 · Clinical Cancer Research

Abstract

PURPOSE: Advanced melanoma is a highly drug-refractory neoplasm representing a significant unmet medical need. We sought to identify melanoma-associated cell surface molecules and to develop as well as preclinically test immunotherapeutic reagents designed to exploit such targets. EXPERIMENTAL DESIGN AND RESULTS: By transcript profiling, we identified glycoprotein NMB (GPNMB) as a gene that is expressed by most metastatic melanoma samples examined. GPNMB is predicted to be a transmembrane protein, thus making it a potential immunotherapeutic target in the treatment of this disease. A fully human monoclonal antibody, designated CR011, was generated to the extracellular domain of GPNMB and characterized for growth-inhibitory activity against melanoma. The CR011 monoclonal antibody showed surface staining of most melanoma cell lines by flow cytometry and reacted with a majority of metastatic melanoma specimens by immunohistochemistry. CR011 alone did not inhibit the growth of melanoma cells. However, when linked to the cytotoxic agent monomethylauristatin E (MMAE) to generate the CR011-vcMMAE antibody-drug conjugate, this reagent now potently and specifically inhibited the growth of GPNMB-positive melanoma cells in vitro. Ectopic overexpression and small interfering RNA transfection studies showed that GPNMB expression is both necessary and sufficient for sensitivity to low concentrations of CR011-vcMMAE. In a melanoma xenograft model, CR011-vcMMAE induced significant dose-proportional antitumor effects, including complete regressions, at doses as low as 1.25 mg/kg. CONCLUSION: These preclinical results support the continued evaluation of CR011-vcMMAE for the treatment of melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-2018

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 183

Metadata

Authors
Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C. S., Shenoy, S. G., Kuang, B., Boldog, F. L., MacDougall, J. R., Rastelli, L., Herrmann, J., Gallo, M., Gazit-Bornstein, G., Senter, P. D., Meyer, D. L., Lichenstein, H. S., & LaRochelle, W. J.
Venue
Clinical Cancer Research
Published
2006-02-15
Volume
12
Issue
4
Pages
1373-1382
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2106529185
Cited by
183
References
0
FWCI
7.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2018
The paper
Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C. S., Shenoy, S. G., Kuang, B., Boldog, F. L., MacDougall, J. R., Rastelli, L., Herrmann, J., Gallo, M., Gazit-Bornstein, G., Senter, P. D., Meyer, D. L., Lichenstein, H. S., & LaRochelle, W. J. (2006). CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.